Teva outlines 2026 EPS of $1.92-$2.11 and projects biosimilars at $800M in sales
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Teva Pharmaceutical Industries Limited (TEVA) Q3 2026 MANAGEMENT VIEW * "AUSTEDO, AJOVY and UZEDY all delivering strong Q3 performance and our innovative portfolio is up 33%. And we're raising full year guidance across all of these products." (President…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRaised guidance on key products is a positive factor for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Teva projects 2026 EPS between $1.92 and $2.11.
- 02The company is raising full-year guidance for AUSTEDO, AJOVY and UZEDY.
- 03Teva discontinued the Phase II emrusolmin study after an interim futility analysis.
- 04Teva has reached investment-grade status across all three major rating agencies.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets